Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma. Neoantigens have long been considered optimal targets for anti-tumour vaccines, and recent mutation coding and prediction techniques have aimed to streamline their identification and selection. Two papers in this issue report results from personalized neoantigen vaccine trials in patients with cancer. Catherine Wu and colleagues...